If you’re not following Dr Alo, check him out. Always great information
🚨 Ezetimibe has been called a "numbers drug" that lowers LDL but does not save lives.
IMPROVE-IT proved that wrong in over 18,000 patients.
Heart attacks dropped 13%. Strokes dropped 21%. And no, it is not just moving a number on your lab report.
"But the data says otherwise."
I am a cardiologist. I have hundreds of patients on ezetimibe right now, most of them paired with rosuvastatin from day one.
🔬 Here is the mechanism. Statins block cholesterol production in your liver. Ezetimibe blocks cholesterol absorption in your gut through NPC1L1. Two different doors, same wall. The effects stack.
🩺 This is why I do not just double the statin dose when a patient needs more LDL lowering.
✅ Doubling a statin dose: about 10% additional LDL reduction
✅ Adding ezetimibe instead: about 26% additional LDL reduction
That comes from a pooled analysis of 17 trials and gets confirmed again in the ACTE trial. Ezetimibe wins by a wide margin.
💓 IMPROVE-IT is the trial that changed everything. 18,144 patients already had a heart attack or unstable angina. All were on simvastatin. Adding ezetimibe dropped LDL to 53.7 mg/dL compared to 69.5 mg/dL.
✅ Heart attacks cut 13%
✅ Ischemic strokes cut 21%
✅ First major cardiovascular event fell from 34.7% to 32.7% at 7 years
No difference in death from any cause. I am not going to pretend otherwise. The benefit is real but it is specific: fewer nonfatal heart attacks and strokes, not longer life.
🫀 The benefit was not spread evenly. It concentrated hard in high-risk patients.
Diabetics: 5.5 fewer events per 100 people, compared to only 0.7 in nondiabetics.
Age 75 and older: 8.7 fewer events per 100 people. The largest benefit of any subgroup in the entire trial.
Three or more risk factors: 6.3 fewer events per 100 people, with only 16 people needing treatment for 7 years to prevent one event.
That matters because the question is no longer does ezetimibe work. The question is who benefits the most. And the answer is your sickest, oldest, highest-risk patients.
🩺 RACING backs this up from a different angle. A moderate dose of rosuvastatin plus ezetimibe matched high-dose rosuvastatin alone for events, 9.1% versus 9.9%. More patients hit goal LDL under 70, 72% versus 58%. And fewer people quit from side effects, 4.8% versus 8.2%.
❌ ENHANCE in 2008 is where the "ezetimibe doesn't work" myth came from. That trial measured carotid artery wall thickness in familial hypercholesterolemia patients. It never measured a single heart attack or stroke. IMPROVE-IT measured real outcomes in a population 25 times larger. You cannot compare an imaging study to an outcomes trial and call it settled.
⚠️ One more correction I make constantly. CLEAR Outcomes tested bempedoic acid, not ezetimibe. Different drug. They do get combined in Nexlizet, which lowered LDL about 38% more than placebo. But do not let anyone tell you CLEAR Outcomes is ezetimibe data. It is not.
🔸 SHARP, EWTOPIA 75, and a Cochrane review of 26 trials covering 23,499 people all point the same direction. Fewer major cardiovascular events. No clear mortality benefit. Consistent pattern across different populations.
❤️ Bottom line:
Ezetimibe is not a numbers drug. It is not fake cardiology.
It has been tested in tens of thousands of patients across multiple major trials.
It lowers LDL more than doubling your statin.
It prevents nonfatal heart attacks and strokes, especially if you are diabetic, over 75, or carry multiple risk factors.
Side effect rates match placebo across the data.
I start most of my patients on rosuvastatin and ezetimibe together. I do not wait to max out the statin first.
The question is not whether ezetimibe works. The question is why more doctors are not using it this way.
#Cardiology #HeartDisease #HeartHealth #C
1
102
CJ Weber retweeted
🚨 Ozempic is not a weight loss drug. It is a cardiovascular drug that happens to shrink your waistline.
The SELECT trial proved it. A 20% drop in heart attacks, strokes, and cardiovascular death in people who did not even have diabetes.
But the data says otherwise to what you think you know. And no, this is not just about vanity.
I am a cardiologist. I have patients on these medications for their hearts, not their jeans size.
💓 Here is what the science actually says.
SELECT Trial (semaglutide): Over 17,000 obese patients with no diabetes. 20% reduction in major cardiovascular events. That matters because it proves the benefit is not dependent on fixing blood sugar.
🩺 The protection goes deeper than the scale.
✅ Heart attacks reduced by 15%
✅ Strokes reduced by 16%
✅ Heart failure hospitalizations dropped by 15%
✅ Acute kidney failure risk dropped by 9%
🔬 Not every GLP-1 carries the same evidence.
The strongest cardiovascular data belongs to semaglutide, dulaglutide, and liraglutide. The FDA approved semaglutide and dulaglutide specifically to reduce cardiovascular risk. This is not a class effect by assumption. It is earned trial by trial.
Before Ozempic, there was Victoza. Liraglutide and the LEADER trial started this entire story. Over 9,000 Type 2 diabetics followed for almost four years. Cardiovascular death dropped 22%. Major heart events dropped 13%. Patients with kidney disease saw even stronger protection.
And LEADER changed everything, because it proved this was never just about blood sugar control.
🔬 A 2025 meta-analysis pooled 21 trials and nearly 100,000 patients. Result: a consistent 12% to 14% drop in major heart events, rated high certainty evidence. SOUL trial: oral semaglutide cut MACE by 14%. FLOW trial: semaglutide cut major kidney events by 24% and cardiovascular events by 18%.
The mechanism is not just pounds lost. These drugs lower inflammation, blood pressure, and insulin resistance directly. Protection starts before patients hit their max weight loss.
⚠️ Now the fear everyone repeats: Ozempic melts your muscle.
Dr. Kevin Hall's research says otherwise. GLP-1 users lose lean mass at the same 20% to 30% ratio as any other major weight loss method. That is not unique to this drug class. And for the vast majority of people, that loss is not clinically dangerous.
🔸 The question is no longer does it cause muscle loss. The question is does it cause more muscle loss than dieting without it. It does not.
❌ It does not melt your muscle more than dieting.
❌ It is not a cosmetic shortcut.
❌ It is not a diabetes-only drug.
These are not miracle drugs. There is no such thing. This is a very, very sharp tool.
❤️ Bottom line:
The muscle loss fear is overblown. The cardiovascular benefit is proven in trials spanning over 125,000 patients combined.
My protocol for patients on these medications: high protein intake near 1 gram per pound of ideal body weight. Mandatory resistance training. Slow dose titration.
Do that and you protect your heart and your muscle at the same time.
The question is not whether you should fear this drug. The question is whether you are using it correctly.
#Cardiology #HeartDisease #HeartHealth #CardiovascularHealth #GLP1 #Ozempic #Semaglutide #Obesity #PreventiveCardiology #MetabolicHealth
CJ Weber retweeted
Repatha Praluent Inclisarin are medications called PCSK9 inhibitors. They can help reduce LDL c #CardioTwitter #MedTwitter
CJ Weber retweeted
🚨 Crestor and Lipitor are not interchangeable, and the one your doctor picked might be wrong for you.
Rosuvastatin crushes LDL harder per milligram than atorvastatin.
But in a head-to-head trial, they prevented the exact same number of heart attacks over 3 years.
CJ Weber retweeted
Introducing TrustPointe Quality+
Before you commit to a long-term peptide supplier, find out if they can actually hold spec.
We send an auditor on-site during production, pull 30 vials off the line, and test them in our lab with fully validated methods.
You get an FDA cGMP-based audit, ranked risks, and real capability data. Not just a COA.
Details: trustpointeanalytics.com/pag…
CJ Weber retweeted
Something I found interesting about the Lilly lawsuits: they never present objective evidence of their safety claims.
They clearly have the resources to test grey market samples.
Like “marketed as reta but isn’t reta based on MS”.
CJ Weber retweeted
Vox populi, vox dei
Use code TPX1000 for 30% off all peptide testing, all week 👨🔬🥼🧪
trustpointeanalytics.com/
CJ Weber retweeted
We’re working on something that might change how vendors in this space are viewed
More details on Tuesday
No such thing as a trusted vendor, only a tested batch.
- @rorynotsorry




















